BioSpace News Archive

According to Latest Study, the sepsis diagnostic market size is projected to reach US$ 1.2 billion by 2030 and it is growing at a registered CAGR of 7.8% from 2021 to 2030.

The global exosome diagnostic and therapeutic market size was estimated at $224.34 million in 2020, and is projected to reach $2.9 billion by 2030, growing at a CAGR of 29.4% from 2021 to 2030.

The global cardiac surgical devices market was estimated at US$ 2.2 billion in 2020, and is projected to reach US$ 3.1 billion by 2030, growing at a CAGR of 3.3% from 2021 to 2030.

According to QY Research Medical, the in vitro toxicity testing market size is projected to hit $59,147.6 million by 2030, growing at a CAGR of 12.2% from 2020 to 2030.

The global transdermal drug delivery systems market size was accounted US$ 52,476.50 million in 2020, and is projected to garner US$ 87,322.40 million by 2030, growing at a CAGR of 5% from 2021 to 2030.

Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, announced that members of the management team will participate in the upcoming 19th Annual Craig-Hallum Institutional Investor Conference on June 1st, 2022.

IQVIA Holdings Inc., announced that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Jefferies Healthcare Conference in New York City on Friday, June 10, 2022 at 11:30 a.m. ET.

InnoCare Pharma announced that it has received approval to conduct a single-arm, open-label, multicenter phase II clinical trial evaluating the safety and efficacy of tafasitamab in combination with lenalidomide by China’s National Medical Products Administration for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation.

Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, will participate in two upcoming healthcare conferences.

Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurological health disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer will present at the William Blair 42nd Annual Growth Stock Conference.